Senate FDA reform effort has input of FDA Associate Commissioner Wykoff, working for Kennedy.
Executive Summary
FDA REPRESENTATION IN SENATE REFORM DEBATE IS IMPROVED by the temporary assignment of a top FDA staff official, Randy Wykoff, to Sen. Kennedy's (D-Mass.) minority staff on the Senate Labor & Human Resources Committee. Wykoff has been involved in FDA's effort to coordinate AIDS initiatives for almost five years as associate commissioner, Office of AIDS & Special Health Issues. He has been assigned to Kennedy's staff since April to provide a background in FDA affairs previously filled by Mark Childress. Wykoff is an MD and has a degree in public health administration.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth